Publication | Open Access

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Lymphoid NeoplasiaMedicineImmunologyPathologyImmune Checkpoint InhibitorPharmacotherapyPd1 BlockadeRelapsed Follicular LymphomaCancer TreatmentPhase 2ImmunotherapyOncologyRadiation Oncology